索利德生物科学

US · SLDB #3476 按市值排名上市于 2018

5.53 -0.21 -3.66%

实时 - 追踪5344个代码 - 心跳于61秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了1家。
机构持股总比例下降了2.7个百分点。

机构持股

机构持股比例: 108.51% -2.66pp
机构数量: 185 -1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund42.21%

Mutual Fund38.81%

Hedge Fund24.16%

Public Company2.37%

Individual/Insider0.91%

Private Company0.60%

Insurance Company0.19%

主要股东截至 2026-06-30

RA Capital Management, L.P. 11.23% · 12.04M 股

Perceptive Advisors LLC 11.10% · 11.91M 股

Bain Capital Life Sciences Investors, LLC 9.15% · 9.81M 股

Artal Group S.A. 7.17% · 7.69M 股

BlackRock 6.47% · 6.93M 股

FMR 6.41% · 6.88M 股

Vanguard Capital Management, LLC 4.20% · 4.50M 股

Armistice Capital LLC 3.99% · 4.28M 股

State Street Global Advisors 3.89% · 4.18M 股

Janus Henderson Group plc 3.77% · 4.04M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 20次买入 · 29次卖出

姓名	职务	持股比例
RA Capital Management, L.P.	--	11.23%
Perceptive Advisors LLC	--	11.10%
Alexander Cumbo	Chief Executive Officer	0.22%
Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	0.14%
Ian Smith	Executive Chairperson	0.13%
David Howton	COO & Secretary	0.10%
Kevin Tan	Chief Financial Officer	0.09%
Gabriel Brooks	Chief Medical Officer	0.08%
Jessie Hanrahan	Chief Regulatory Officer	0.07%
Paul Herzich	Chief Technology Officer	0.07%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-10-01	Ian Smith	Executive Chairperson	Derivative Exercise and Retained	+3,440	--
2026-07-01	Ian Smith	Executive Chairperson	Derivative Exercise and Retained	+3,440	--
2026-06-21	RA Capital Management, L.P.	--	Initial Statement of Beneficial	0	--
2026-06-09	Ian Smith	Executive Chairperson	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Perceptive Advisors LLC	--	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Martin Freed	Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Sukumar Nagendran	Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Adam Stone	Lead Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Lynne Sullivan	Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	Georgia Keresty	Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-06-09	G. Kahn	Independent Director	Other Derivative Acquisition	+77,500	$6.61
2026-04-01	Ian Smith	Executive Chairperson	Derivative Exercise and Retained	+3,441	--
2026-03-08	Joseph Edelman	--	Other Derivative Acquisition	+8,912,655	$0.00
2026-02-17	David Howton	COO & Secretary	Derivative Exercise and Sale	-7,469	$5.82
2026-02-17	David Howton	COO & Secretary	Intent to Sell (Form 144)	-7,469	$5.82
2026-02-17	Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	Derivative Exercise and Sale	-2,658	$5.82
2026-02-17	Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	Intent to Sell (Form 144)	-2,658	$5.92
2026-02-17	Alexander Cumbo	Chief Executive Officer	Derivative Exercise and Sale	-16,644	$5.82
2026-02-17	Alexander Cumbo	Chief Executive Officer	Intent to Sell (Form 144)	-16,644	$5.82

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。